Molecule Radar
Canadian drug pipeline intelligence — Health Canada submissions (NOC / NDS / SNDS), enriched live with DPD brand names and ClinicalTrials.gov, with one-click Apollo contact search.
1,636
Submissions
877
Distinct molecules
164
Under review
1,335
NOC issued
Quick flags1,636 of 1,636 submissions
| › | Bevacizumab ABEVMY, AVASTIN, AYBINTIO +5 · Alymsys +2intl Biosimilar | SANDOZ CANADA INCORPORATED | Antineoplastic agents | Apr 2026 New | Under review |
| › | Gefurulimab NAS | ALEXION PHARMA GMBH | Immunosuppressants | Apr 2026 New | Under review |
| › | Haemagglutinin-strain A(H1N1), haemagglutinin-strain A(H3N2), haemagglutinin-strain B | SEQIRUS UK LIMITED | Vaccines | Apr 2026 New | Under review |
| › | Methenamine hippurate HIP REX TAB 1GM · Hiprex +1intl 3rd-party data | PHARMARIS CANADA INC | Antibacterials for systemic use | Apr 2026 New | Under review |
| › | Omalizumab OMLYCLO, XOLAIR Biosimilar | ADVANZ PHARMA CANADA INC. | Drugs for obstructive airway diseases | Apr 2026 New | Under review |
| › | Sebetralstat Ekterlyintl NASHTA-aligned | PENDOPHARM DIVISION OF PHARMASCIENCE INC | Other hematological agents | Apr 2026 New | Under review |
| › | Sibeprenlimab Voyxactintl NASNOC/cHTA-aligned | OTSUKA PHARMACEUTICAL CO LTD | Immunosuppressants | Apr 2026 New | Under review |
| › | Eculizumab BEKEMV, EPYSQLI, SOLIRIS · Bkemvintl Biosimilar | SAMSUNG BIOEPIS CO., LTD | Immunosuppressants | Apr 2026 Supplemental | Under review |
| › | Efgartigimod alfa VYVGART, VYVGART SC · Vyvgart Hytrulointl | ARGENX BV | Immunosuppressants | Apr 2026 Supplemental | Under review |
| › | Enfortumab vedotin PADCEV | PFIZER CANADA ULC | Antineoplastic agents | Apr 2026 Supplemental | Under review |
| › | Inclisiran sodium LEQVIO | NOVARTIS PHARMACEUTICALS CANADA INC | Lipid modifying agents | Apr 2026 Supplemental | Under review |
| › | Lisocabtagene maraleucel BREYANZI | BRISTOL-MYERS SQUIBB CANADA | Antineoplastic agents | Apr 2026 Supplemental | Under review |
| › | Obinutuzumab GAZYVA | HOFFMANN-LA ROCHE LIMITED | Antineoplastic agents | Apr 2026 Supplemental | Under review |
| › | Pembrolizumab KEYTRUDA, KEYTRUDA SC · Keytruda Qlexintl | MERCK CANADA INC | Antineoplastic agents | Apr 2026 Supplemental | Under review |
| › | Teclistamab TECVAYLI | JANSSEN INC | Antineoplastic agents | Apr 2026 Supplemental | Under review |
| › | Trastuzumab deruxtecan ENHERTU PriorityHTA-aligned | ASTRAZENECA CANADA INC | Antineoplastic agents | Mar 2026 Supplemental | Under review |
| › | Trastuzumab deruxtecan ENHERTU | ASTRAZENECA CANADA INC | Antineoplastic agents | Mar 2026 Supplemental | Under review |
| › | Setmelanotide acetate IMCIVREE PriorityHTA-aligned | RHYTHM PHARMACEUTICALS, INC | Antiobesity preparations, excluding diet products | Mar 2026 Supplemental | Under review |
| › | Pirtobrutinib JAYPIRCA | ELI LILLY CANADA INC | Antineoplastic agents | Mar 2026 Supplemental | Under review |
| › | Pembrolizumab KEYTRUDA, KEYTRUDA SC · Keytruda Qlexintl | MERCK CANADA INC | Antineoplastic agents | Mar 2026 Supplemental | Under review |
| › | Lisocabtagene maraleucel BREYANZI | BRISTOL-MYERS SQUIBB CANADA | Antineoplastic agents | Mar 2026 Supplemental | Under review |
| › | Epcoritamab EPKINLY PriorityHTA-aligned | ABBVIE CORPORATION | Antineoplastic agents | Mar 2026 Supplemental | Under review |
| › | Brexpiprazole REXULTI | OTSUKA PHARMACEUTICAL CO LTD | Psycholeptics | Mar 2026 Supplemental | Under review |
| › | Berotralstat hydrochloride ORLADEYO HTA-aligned | BIOCRYST PHARMACEUTICALS INC | Other hematological agents | Mar 2026 Supplemental | Under review |
| › | Belzutifan WELIREG | MERCK CANADA INC | Antineoplastic agents | Mar 2026 Supplemental | Under review |
| › | Cagrilintide, semaglutide NAS | NOVO NORDISK CANADA INC | Drugs used in diabetes | Mar 2026 New | Under review |
| › | Nivolumab OPDIVO, OPDIVO SC, OPDUALAG · Opdivo Qvantigintl BiosimilarHTA-aligned | AMGEN CANADA INC | Antineoplastic agents | Mar 2026 New | Under review |
| › | Omeprazole APO-OMEPRAZOLE, DOM-OMEPRAZOLE DR, ESOMEPRAZOLE DR +14 · Nexium +1intl | XEOLAS PHARMACEUTICALS LIMITED | Drugs for acid related disorders | Mar 2026 New | Under review |
| › | Sodium benzoate, sodium phenylacetate GLYCOTHYMOLINE, PLAX ANTI-PLAQUE DENTAL RINSE · Ammonulintl NASPriority3rd-party data | STERIMAX INC | Other alimentary tract and metabolism products | Mar 2026 New | Under review |
| › | Baricitinib OLUMIANT | ELI LILLY CANADA INC | Immunosuppressants | Mar 2026 Supplemental | Under review |
| › | Acoltremon Tryptyrintl NAS | ALCON CANADA INC | Ophthalmologicals | Feb 2026 New | Under review |
| › | Datopotamab deruxtecan Datrowayintl NASHTA-aligned | ASTRAZENECA CANADA INC | Antineoplastic agents | Feb 2026 New | Under review |
| › | Finasteride ACCEL-FINASTERIDE TABLETS USP, ACH-FINASTERIDE, ACT FINASTERIDE +17 · Entadfiintl | SEARCHLIGHT PHARMA INC | Other dermatological preparations | Feb 2026 New | Under review |
| › | Nitrofurantoin EQUIFUR NITROFURANTOIN SUSPENSION, FURAFLU SUS 15MG/ML, MACROBID +15 | PHARMARIS CANADA INC | Antibacterials for systemic use | Feb 2026 New | Under review |
| › | Pegloticase Krystexxaintl NASHTA-aligned | AMGEN CANADA INC | Antigout preparations | Feb 2026 New | Under review |
| › | Rucaparib camsylate NAS | PHARMAAND GMBH | Antineoplastic agents | Feb 2026 New | Under review |
| › | Trilaciclib dihydrochloride Coselaintl NAS | PHARMACOSMOS A/S | All other therapeutic products | Feb 2026 New | Under review |
| › | Dupilumab DUPIXENT | SANOFI-AVENTIS CANADA INC | Other dermatological preparations | Feb 2026 Supplemental | Under review |
| › | Peginterferon alfa-2a PEGASYS, PEGASYS RBV | PHARMAAND GMBH | Immunostimulants | Feb 2026 Supplemental | Under review |
| › | Roflumilast DAXAS, ZORYVE · Dalirespintl | ARCUTIS CANADA, INC. | Antipsoriatics | Feb 2026 Supplemental | Under review |
| › | Teclistamab TECVAYLI Priority | JANSSEN INC | Antineoplastic agents | Feb 2026 Supplemental | Under review |
| › | Tirzepatide MOUNJARO, MOUNJARO KWIKPEN, ZEPBOUND | ELI LILLY CANADA INC | Drugs used in diabetes | Feb 2026 Supplemental | Under review |
| › | Trastuzumab deruxtecan ENHERTU HTA-aligned | ASTRAZENECA CANADA INC | Antineoplastic agents | Feb 2026 Supplemental | Under review |
| › | Upadacitinib RINVOQ | ABBVIE CORPORATION | Immunosuppressants | Feb 2026 Supplemental | Under review |
| › | Ustekinumab FINLIUS I.V., IMULDOSA, IMULDOSA IV +9 · Pyzchiva +2intl | JANSSEN INC | Immunosuppressants | Feb 2026 Supplemental | Under review |
| › | Anagrelide hydrochloride AGRYLIN, DOM-ANAGRELIDE, MYLAN-ANAGRELIDE +3 | SEPTA PHARMACEUTICALS INC | Antineoplastic agents | Jan 2026 New | Under review |
| › | Capsaicin ANTIPHLOGISTINE RUB A-535 CAPSAICIN LIQUID, ARTHRICARE FOR WOMEN MULTI-ACTION, ARTHRICARE FOR WOMEN ULTRA STRENGTH +17 · Arth-RX +26intl HTA-aligned | SEARCHLIGHT PHARMA INC | Anesthetics | Jan 2026 New | Under review |
| › | Insulin efsitora alfa NASHTA-aligned | ELI LILLY CANADA INC | Drugs used in diabetes | Jan 2026 New | Under review |
| › | mRNA encoding haemagglutinin of B/Victoria lineage, haemagglutinin of influenza A/H1N1, haemagglutinin of influenza A/H3N2, SARS-CoV-2 spike protein NTD-RBD subdomains NASCOVID-19 | MODERNA BIOPHARMA CANADA CORPORATION | Vaccines | Jan 2026 New | Under review |
| › | mRNA encoding haemagglutinin of B/Victoria lineage, influenza A/H1N1, influenza A/H3N2 NAS | MODERNA BIOPHARMA CANADA CORPORATION | Vaccines | Jan 2026 New | Under review |
Page 1 of 33